Skip to content

Pretreatment FDG-PET Biomarkers Predict Regional and Distant Failure but Not Local Recurrence Following Modern Use of Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.

Oct 2026 · Clinical Lung Cancer · Vol 27 10, pp. 16-24 · 0 citations · 45 references
Medicine

Abstract

Background

Quantitative fluorodeoxyglucose positron emission tomography (FDG-PET) biomarkers are associated with prognosis following stereotactic body radiotherapy (SBRT) for early-stage non-small cell lung cancer (ES-NSCLC); however, their relationship with patterns of failure remains poorly defined. We evaluated the prognostic significance of pretreatment metabolic PET parameters following definitive SBRT. PATIENTS AND

Methods

Patients with T1-3N0M0 ES-NSCLC treated with SBRT between January 2010 and December 2024 were identified from a prospectively maintained institutional database. Pretreatment FDG-PET metrics including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were stratified into low-, intermediate-, and high-risk groups. Overall survival (OS); cancer-specific survival; and local, regional, and distant failure were analyzed using competing-risk methods and multivariable Fine-Gray regression.

Results

A total of 168 patients were included (median age, 77 years; median follow-up, 34.6 months). Local, regional, and distant failure occurred in 3.6%, 10.1%, and 15.5% of patients, respectively. Increasing TLG, SUVmax, SUVmean, and MTV were associated with inferior OS on univariable analysis, while high-risk TLG (HR, 2.26; P = .014) and SUVmean (HR, 2.72; P = .008) remained independent predictors of worse OS. No PET biomarker predicted local failure. Conversely, high-risk TLG and MTV independently predicted regional recurrence, while high-risk TLG, SUVmax, and SUVmean independently predicted distant metastasis.

Conclusion

Pretreatment FDG-PET metabolic biomarkers identify patients at increased risk of regional and distant recurrence following SBRT for ES-NSCLC but do not predict local failure after modern ablative radiotherapy. TLG demonstrated the most consistent prognostic performance and may represent a clinically useful biomarker for risk-adapted staging, surveillance, and future treatment intensification strategies.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.